Sunday, September 15, 2019, Chicago, Illinois, 6:30 PM – 8:00 PM

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer

Hyatt Regency McCormick Place
2233 South Dr Martin Luther King Jr Drive
Chicago, IL 60616
Phone: (312) 567-1234

6:00 PM – 6:30 PM — Registration and Dinner Buffet
6:30 PM – 8:00 PM — Educational Program

Meeting Room
Regency Ballroom C-E (second floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Shruti Jolly, MD
Professor, Department of Radiation Oncology
Chief of Brachytherapy Services
Associate Chair of Community Practices
Associate Medical Director
UMHS Strategic Planning and Business Development
University of Michigan
Ann Arbor, Michigan

Billy Wiseman Loo Jr, MD, PhD
Professor, Thoracic Radiation Oncology
Program Leader
Department of Radiation Oncology
Stanford University School of Medicine
Stanford, California

Jyoti D Patel, MD
Professor of Medicine
Director, Thoracic Oncology
The University of Chicago
Chicago, Illinois

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

The American Society for Radiation Oncology (ASTRO) has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium. The symposium constitutes the content and views of the provider and is not part of the official ASTRO Annual Meeting program.

Meeting Agenda and Format

Prior to this event, the faculty members and 3 other lung cancer investigators will be asked to complete a case-based Consensus or Controversy (CoC) survey designed to document their usual approaches to a variety of clinical scenarios and management questions. During the program, the responses to specific CoC questions will be graphically displayed for the audience. Short didactic presentations will also be included to provide a formal review of available data and ongoing trials.

MODULE 1: Established Management Paradigms and Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Jolly

  • Initial workup and staging of suspected Stage III NSCLC; key factors affecting the determination of surgical resectability
  • Historical outcomes associated with concurrent chemoradiation therapy and consolidation chemotherapy for patients with unresectable Stage III disease; effect of stage on prognosis
  • Optimal administration of radiation therapy for patients with unresectable Stage III disease; efficacy and safety outcomes observed with various doses and methods of delivery
  • Theoretical effects of radiation therapy on the tumor and stroma microenvironment; role in immune system activation and sensitization of cancer cells to immunotherapy
  • Preclinical and early clinical research efforts documenting the synergistic effect of chemoradiation therapy and immune checkpoint inhibition

MODULE 2: Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Langer

  • Design of, eligibility criteria for and key efficacy and safety findings from the Phase III PACIFIC trial evaluating the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
  • Updated overall survival findings with the use of durvalumab consolidation in the PACIFIC study
  • Efficacy and current role of durvalumab in prespecified subgroups (eg, histology, smoking status, PD-L1 status, disease with a targetable genomic alteration)
  • Optimal timing for the use of durvalumab consolidation; effect of underlying pneumonitis, esophagitis or asymptomatic radiographic changes on the potential introduction of anti-PD-L1 therapy in this setting
  • Patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III NSCLC

MODULE 3: Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-L1 Antibody Therapy for Locally Advanced Disease — Dr Patel

  • Rates of Grade 3/4 adverse events (AEs), including pneumonitis and other immune-mediated AEs among patients receiving durvalumab in the PACIFIC study
  • Frequency of treatment discontinuation among patients receiving durvalumab versus placebo in the PACIFIC study
  • Recognition and management of immune-mediated or other AEs with durvalumab consolidation; recommendations for dose interruptions or treatment discontinuation
  • Recent ASCO guidelines on the management of immune-related AEs in patients receiving immune checkpoint inhibitor therapy; applicability to patients with Stage III disease
  • Available data with the use of immune checkpoint inhibitors in patients with preexisting autoimmune diseases or those who have undergone solid organ transplant

MODULE 4: Ongoing and Planned Clinical Trials of Immune Checkpoint Inhibitors for Patients with Nonmetastatic NSCLC — Dr Loo

  • Rationale for and ongoing investigation of anti-PD-1/PD-L1 antibodies administered concurrently with chemoradiation therapy for unresectable Stage III NSCLC
  • Early safety and efficacy data with and ongoing evaluation of immune checkpoint inhibitors as neoadjuvant therapy for locally advanced NSCLC
  • Ongoing trials evaluating the potential role of immune checkpoint inhibition as adjuvant therapy after surgical resection
  • Status of active clinical trials evaluating the use of other anti-PD-1/PD-L1 antibodies as consolidation therapy after chemoradiation therapy for patients with unresectable Stage III disease

Target Audience
This activity is intended for radiation oncologists, medical oncologists, oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Consult pathologic assessments, imaging and other paraclinical tools to accurately stage newly diagnosed NSCLC, and use this information to design an appropriate treatment plan for patients.
  • Appreciate the benefits, risks and long-term outcomes associated with local and systemic treatment modalities in the management of resectable or unresectable locally advanced NSCLC, and consider this information when counseling patients regarding current therapeutic recommendations.
  • Analyze the biologic basis for the investigation of immune checkpoint inhibitors for nonmetastatic NSCLC.
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Recognize immune-related adverse events and other common side effects associated with consolidation anti-PD-L1 antibody therapy for patients with Stage III NSCLC, and offer supportive strategies to minimize and manage these toxicities.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for localized or locally advanced NSCLC, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Hyatt Regency McCormick Place
2233 South Dr Martin Luther King Jr Drive
Chicago, IL 60616
Phone: (312) 567-1234

Meeting Room
Regency Ballroom C-E (second floor)

The symposium will take place at the Hyatt Regency McCormick Place hotel, which is connected to the McCormick Place convention center, where the ASTRO Annual Meeting is taking place.


This activity is intended for radiation oncologists, medical oncologists, oncology fellows and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.